Disclaimer: This analysis was produced using autonomous AI agents and publicly available information. It is intended for informational and educational purposes only and should not be used to make investment decisions. CompetitiveIntelligence.com is an independent publication. For our relationship with Atacana Group, see our About page.
Company Name: GlobalData Plc
Ticker: LSE: DATA (FTSE 250)
Headquarters: London, UK
Founded: 2016 (current form); heritage to 1990 via Datamonitor
Founder & CEO: Mike Danson (~63% equity stake) simplywall.st/stocks/us/commercial-services/otc-glda.f/globaldata/management
Ownership: Public — LSE Main Market (moved from AIM in March 2026); joined FTSE 250 in June 2026
Revenue (FY2025): £322.1M (~$410M), +13% reported, +1% organic
Healthcare Revenue (FY2025): £123.3M (~$157M); EBITDA margin ~56%
H1 2026 Revenue: £162.9M (+4% reported, +1% underlying)
H1 2026 Adj EBITDA: £54.8M (+5%), 34% margin
Market Cap: ~£420M (~$540M) as of Oct 2026
Share Price: ~GBX 65–67p (Oct 2026); 52-week range: 52.61p–154.00p
Employees: 3,558 (Dec 2025); ~3,100–3,900 depending on source
Enterprise Customers: ~4,900 total; 2,000+ in healthcare
Industries Covered: Healthcare/Pharma, Consumer, Technology, Financial Services, Industrials
Segments (Financial Reporting): Data, Analytics & Insights: Healthcare; Data, Analytics & Insights: Non-Healthcare
CEO & Founder — Mike Danson: Founded Datamonitor in 1990; IPO'd it in 2000; sold to Informa for £502M in 2007; re-acquired Datamonitor assets and formed GlobalData in 2016. Holds ~63% equity
CFO — Robert Kingston: Joined Sep 7, 2026; formally appointed to Board Sep 30. Ex-Keywords Studios CFO, ex-Sky PLC
CSO — Jonathan Hardinges: Chief Strategy Officer
Dir. Product Innovation — Sudeep Shouche: Leads AI and platform strategy
VP & Head of Deallus — Peter Barschdorff: NYC-based; leads Deallus consulting within GlobalData Healthcare
Non-Executive Chair — Murray Legg:
Deallus was founded in 2004 in London as a life sciences competitive intelligence consultancy. Over two decades, it became a trusted CI partner to 25 of the world's top 30 pharmaceutical companies, with offices in London, New York, Los Angeles, and Tokyo archimed.group/companies/deallus. Previously backed by private equity firm Archimed, Deallus was acquired by GlobalData's Healthcare division in January 2025 for £20.8M. Deallus now operates under the sub-brand "Deallus, a GlobalData company" as one of three named consulting solutions alongside Core CI and Cambridge Healthcare Research (CHR).
Understanding what GlobalData is trying to become reveals where they'll invest, what markets they'll enter, and which strategic moves to anticipate.
GlobalData positions itself as "an intelligence and productivity platform that empowers leaders to act decisively in a world of complexity and change". CEO Mike Danson has consistently described the ambition as building a "one platform" that delivers data, analytics, and insights across multiple industries through a single subscription — fundamentally a horizontal breadth play rather than a vertical depth strategy.
The original £500M revenue target has been abandoned. GlobalData had previously set an annualized revenue goal of £500M by end of 2026, but after organic growth stalled at just +1% in FY2025, the company quietly dropped the target. A Media Operator analysis noted GlobalData appeared to have "dropped previously-announced plans to reach £500 million annualized revenue by the end of 2026 as the publicly-listed business contends with 'disappointing' underlying growth".
The revised financial targets center on margin recovery — management aims to expand EBITDA margins back toward 40%, a goal it acknowledged in January 2026. However, the H1 2026 earnings warning revealed that EBITDA would fall below consensus (which was £121–127M for FY2026), with margins at 34% as AI investment costs mount.
GlobalData's most consequential strategic bet is the integration of its data platform business with consulting capabilities acquired through Deallus and Cambridge Healthcare Research. The goal is to become a one-stop shop where pharmaceutical companies can access structured data (drug pipelines, clinical trials, pricing) and bespoke consulting (competitive intelligence, war-gaming, strategic advisory) from the same vendor.
CEO Danson described the Deallus acquisition as creating "the opportunity for the Group to build deeper, more embedded relationships with major brands within the pharmaceutical sector". Deallus CEO Peter Barschdorff and consultants now operate as "Deallus, a GlobalData company" — maintaining the legacy brand while cross-selling into GlobalData's 2,000+ healthcare customer base.
GlobalData is investing heavily in AI, accepting short-term margin pressure to fund the transition. Dir. Product Innovation Sudeep Shouche has described the strategy as "agentic AI at the source of the intelligence, not just at the top layer" — deploying specialized AI agents directly within premium databases rather than layering a chatbot on top.
Management has stated it is "deliberately spending more on artificial intelligence" and that AI will "strengthen pricing power and customer loyalty over time" — even as this investment compressed margins to 34% in H1 2026.
In October 2026, The Times reported that CEO Danson said he would consider offers for any of GlobalData's three core divisions — Healthcare, Consumer, and Technology. Shares jumped 6.4% on the news. The break-up discussion emerged after the share price collapsed ~55% from its 52-week high, creating a visible sum-of-parts discount: the Inflexion deal alone valued the Healthcare division at £1.115B versus a total group market cap of ~£420M. No formal strategic review has been announced; Danson framed it as "open to offers" not "actively seeking sale."
GlobalData has been on an acquisition spree: six deals in approximately 18 months (Celent, LinkUp, Deallus, AI Palette, Stylus, Cambridge Healthcare). The company has expanded its Healthcare revolving credit facility by £60M to £245M and stated it will "continue to pursue value-accretive M&A in our Healthcare division". However, the FY25 annual report also acknowledged a pivot: "We will look to deliver bolt-on acquisitions in FY2026" and focus on driving revenue synergies from recent deals rather than continuing the acquisition pace.
GlobalData competes as a breadth-first differentiator in Porter's generic strategy framework. Unlike vertically specialized pharma intelligence vendors (Citeline, Evaluate, Norstella), GlobalData covers healthcare, consumer, technology, financial services, and industrials through a single "One Platform" subscription. For pharma buyers specifically, the differentiator is the combination of structured data (Intelligence Center) with human consulting (Deallus, CHR) — a hybrid model that most pure-data competitors don't offer.
GlobalData Pharma Intelligence Center — the core platform — aggregates over 290 proprietary datasets across key modules: Drugs Intelligence, Trials Intelligence, Therapeutic Analysis, Price Intelligence (POLI), Patents Database, World Healthcare Markets, Lead Sheet & Catalyst Calendar, and Digital Marketing Intelligence. The platform is described as a "one-stop intelligence center" that pulls together drug pipeline data, clinical trials, regulatory milestones, pricing/HTA decisions, epidemiology, disease forecasting, and company profiles, backed by 2,000+ in-house analysts.
The platform is supplemented by three branded consulting offerings within the Healthcare division:
Ava — Specialized Database Agents. GlobalData's flagship AI product, Ava, was initially launched as a general research assistant and significantly upgraded in January 2026 with agentic capabilities. In April 2026, GlobalData announced the rollout of specialized Ava agents embedded directly within premium databases — a "system of multiple specialized database agents" with entity resolution and a purpose-built semantic layer spanning 250+ databases and 100,000+ analyst-curated reports. In May 2026, a Customer Success agent was added to Ava for in-platform support. AI tools are bundled into 90% of customer contracts.
Sam — AI Sales Analyst. Unveiled in September 2025 as an agentic AI for GTM teams, designed to automate workflows from market identification through lead prioritization. Beta testing reportedly showed increased conversion rates and savings of "hundreds of thousands" on TAM planning costs.
Emerging: AI for Therapy Area / Disease Landscape. Previewed at the Pharma CI Conference USA in 2026 as a masterclass combining Ava data agents with Deallus CI methodology — but no public product page or launch date exists as of November 2026.
GlobalData employs a solutions-led enterprise sales model with 367 salespeople at the start of 2026. The company has been shifting from product-led to solutions-led selling, with pre-sales roles now covering all three healthcare brands (Core CI, Deallus, CHR) in unified pitches. The company has signed contracts exceeding £1M each (3 in H2 2025) and is deepening C-suite engagement.
GlobalData uses an opaque enterprise subscription model — no prices are published on its website, and all subscriptions require a sales conversation. Based on third-party procurement data:
Notably, AI features (Ava) are bundled into the standard subscription and not charged as a premium add-on — a differentiation point versus competitors that meter AI separately.
GlobalData's most unique competitive asset is its owned media empire — a network of industry publications that function as a lead generation engine:
These properties are part of an established B2B media company with over 70 years of experience. For pharma CI specifically, Pharmaceutical Technology and Clinical Trials Arena serve as direct funnels to the Intelligence Center, with gated content, industry reports, and DECODED newsletters driving lead generation. No peer competitor has an equivalent owned media network for pharma audiences.
Porter's third component examines the mental models that guide a competitor's decisions. When these assumptions are wrong, they create exploitable blind spots.
GlobalData's self-image: An "intelligence and productivity platform" and "decision engine" that replaces data siloes with real-time intelligence across all major industries.
Market reality: GlobalData is indeed the broadest cross-industry intelligence provider, and its Healthcare division is genuinely strong with 56% EBITDA margins. However, underlying organic growth has stalled at just 1%, the share price has collapsed ~55% from its 52-week high, and analysts have uniformly cut price targets and growth forecasts. The "one platform" narrative is under pressure from the reality that the company's growth has been acquisition-driven, not organic.
"Breadth + consulting integration wins." GlobalData's core bet is that buyers prefer a single vendor that covers data platforms AND consulting across multiple industries, and that Deallus + CHR consulting layered on top of the Intelligence Center creates a defensible moat. This assumption may prove wrong because pharma CI buyers increasingly value depth over breadth — a specialized pharma platform that goes deep on drug pipelines, clinical trials, and competitive strategy may beat a generalist that covers everything from mining to retail at a shallower level.
"Data scale matters." GlobalData believes 290+ proprietary datasets and 2,000+ analysts create a data advantage that's difficult to replicate. However, in the pharma intelligence market specifically, competitors like Citeline (TrialTrove), Evaluate (Pharma), and IQVIA (Explorer) have decades of deeper, more granular curated data in their respective domains — and emerging AI platforms like AlphaSense are building knowledge graphs that aggregate breadth without requiring massive analyst teams.
"AI at the data source beats AI at the search layer." Shouche's positioning of "agentic AI at the source of the intelligence" assumes that embedding AI agents within proprietary databases is architecturally superior to competitors' approaches of overlaying AI on aggregated content. This is a reasonable technical argument, but the market is moving quickly — and GlobalData's growth stall suggests the AI investment hasn't yet translated into customer acquisition or retention improvements. Healthcare volume renewal remains at 78%.
Deallus integration complexity. GlobalData now sells three distinct consulting brands (Core CI, Deallus, CHR) through the same salesforce. Pre-sales roles explicitly mention covering "Core CI, Deallus or CHR solutions." For buyers, the value proposition of three overlapping consulting brands under one umbrella may be unclear — especially when the historical Deallus brand stood for specialized, independent pharma CI consulting, not a division of a cross-industry data conglomerate.
Customer confusion about the combined offering. A G2 reviewer noted finding "the platform [not] sufficiently useful or relevant to our work" and complained about inflexible subscription termination policies. On Reddit, pharma professionals have noted "GlobalData's accuracy issues are well documented" and that "for a focused biotech the breadth is wasted".
"Is GlobalData legit?" credibility signal. A notable search-engine signal: the query "is globaldata legit" appears in Google's auto-suggest for GlobalData, indicating enough search volume to reflect a persistent credibility concern among prospective buyers. While this may partly relate to a separate Portuguese e-commerce brand with a similar name, the association creates a trust issue in brand-first search contexts.
Employee sentiment. Glassdoor reviews rate GlobalData at 2.5/5 for compensation and benefits, with specific complaints about "products feel like a scam," "fear mongering of constant redundancy," and "poor management". The 2,263 Glassdoor reviews suggest significant employee-base engagement with the platform, and the low rating is a persistent signal of talent retention challenges.
GlobalData's pharma intelligence offering spans both data platforms and human consulting:
Pharma Intelligence Center (Platform) The core subscription product. Key modules include: Drugs Intelligence, Trials Intelligence, Therapeutic Analysis, Price Intelligence (POLI) for global pharmaceutical pricing and HTA decisions, Patents Database, World Healthcare Markets, Lead Sheet & Catalyst Calendar, and Digital Marketing Intelligence. The platform covers the entire drug lifecycle — from preclinical pipeline through marketed drug performance — with geography-specific news, deals, company profiles, and market/product databases.
Deallus Competitive Intelligence Consulting Bespoke CI projects, war-gaming and scenario planning, market intelligence, KOL mapping, strategic advisory. Key therapy areas: oncology, neuroscience, vaccines, rare diseases, cell & gene therapy, immunology. Two decades of heritage serving 25 of the world's top 30 pharma companies archimed.group/companies/deallus. A formalized CI Methodologies Certification Framework has been launched for analyst training.
AI Capabilities (Ava) System of multiple specialized database agents embedded across 250+ databases and 100,000+ analyst-curated reports. Natural language interrogation with entity resolution and purpose-built semantic layer per database. Cited, source-linked answers from proprietary intelligence. Ava Customer Success agent provides in-platform support workflows.
GlobalData is publicly traded with £322.1M in FY2025 revenue. The Inflexion PE deal generated gross cash proceeds of £451.4M for the group, providing an M&A war chest. The Healthcare revolving credit facility was expanded by £60M to £245M, and the Non-Healthcare facility was expanded by £60M.
However, financial headwinds are significant: FY2026 EBITDA is expected to come in below the £121–127M consensus, the share price has collapsed from ~154p to ~65p, and the company took a £228.4M healthcare impairment in FY2025 accounts reflecting "market headwinds" in pharmaceuticals. £49M has been returned to shareholders via buybacks and a tender offer in H1 2026.
Analyst coverage is extensive but sentiment has deteriorated sharply:
Based on customer reviews, independent analysis, financial data, and competitive intelligence:
Credibility concerns in search. The query "is globaldata legit" appears in Google auto-suggest, reflecting persistent trust questions among prospective buyers — even if partly attributable to brand confusion with unrelated entities.
Deallus integration struggles. Operating three consulting brands (Core CI, Deallus, CHR) through one salesforce creates positioning complexity. The sub-brand "Deallus, a GlobalData company" may dilute Deallus's independent CI heritage that attracted top-20 pharma clients. No public customer satisfaction data exists for the post-acquisition period.
Growth has stalled. Underlying organic growth was just +1% in both FY2025 and H1 2026, despite significant M&A activity. The abandoned £500M revenue target and below-consensus EBITDA underscore execution challenges.
Spread thin across industries. For pharma CI buyers, the cross-industry model means that healthcare is one division among several. Consumer division actually grew faster (+7% underlying in H1 2026) than Healthcare, raising questions about management attention and investment priority.
78% healthcare volume renewal = 22% annual churn. This is a significant vulnerability — nearly one in four healthcare clients with >£20K contracts don't renew. Value renewal is improving (~89%) suggesting higher-value clients are stickier, but the volume churn rate remains elevated.
AI hasn't yet driven measurable growth. Despite 90% AI contract penetration and "deliberate" margin sacrifice for AI investment, the company's organic growth rate hasn't improved. Healthcare renewal rates remain unchanged. AI tools appear to be a retention feature bundled to prevent churn, not a growth driver.
Data accuracy concerns. Reddit pharma professionals have noted "GlobalData's accuracy issues are well documented" and that "the breadth is wasted" for focused biotechs. A desktop-first experience that "some find unwieldy" and "less historical depth than legacy databases like Cortellis in some areas" are cited by third-party analysts.
Share price collapse undermines confidence. A 55%+ decline from 52-week highs, an earnings warning, analyst downgrades, and break-up speculation create an environment where clients may question vendor stability and long-term viability.
Based on the analysis of GlobalData's goals, strategy, assumptions, and capabilities, here's how they're likely to behave over the next 12 months.
Accelerated Deallus and CHR cross-sell. GlobalData will push hard to sell Deallus consulting engagements to its existing 2,000+ healthcare platform clients, and vice versa — selling Intelligence Center subscriptions to former Deallus-only clients. The three-brand solutions-led selling model is designed explicitly for this cross-sell motion. Expect bundled deals combining data platform access with consulting retainers.
Healthcare bolt-on acquisitions. The expanded £245M credit facility and stated intent to "deliver bolt-on acquisitions in FY2026" signal at least one more healthcare M&A deal. Likely targets: specialized pharma data or consulting firms that fill gaps in the Intelligence Center or complement Deallus's therapy area coverage.
AI product launches. The previewed "Therapy Area / Disease Landscape AI solution" — combining Ava data agents with Deallus CI methodology — is the highest-priority product to watch. If launched, it would represent GlobalData's first truly differentiated AI+CI hybrid product, directly targeting the competitive intelligence workflow rather than just data querying.
FTSE 250 brand leverage. The Main Market listing and FTSE 250 inclusion give GlobalData institutional credibility that smaller competitors lack. Expect this to be leveraged heavily in enterprise procurement contexts.
Strategic uncertainty (now through Q1 2027). Break-up speculation, earnings warning, CFO transition, and share price collapse create maximum strategic distraction. Client-facing teams may be unsettled. Former Deallus clients may be evaluating alternatives during integration disruption.
Healthcare renewal cycle. With 78% volume renewal and 22% annual churn, there is a persistent window for competitive displacement — particularly in the mid-market segment that GlobalData has explicitly identified as a problem area.
Margin pressure constraining AI investment. Management is simultaneously trying to invest in AI, recover margins, and return cash to shareholders (£49M in H1 2026). Something has to give — and the earnings warning suggests AI investment may be curtailed or slowed to protect profitability.
For CI practitioners and buyers evaluating GlobalData / Deallus, the following areas warrant ongoing monitoring:
US Monthly Search Volume ("globaldata"): 2,400 (Internal keyword research)
Global Monthly Search Volume: 65,400 (Internal keyword research)
Keyword Cluster Volume: 8,700 (Internal keyword research)
Keyword Difficulty: 40% (Internal keyword research)
CPC: $5.93 (Internal keyword research)
Keyword Variations: 1,080 (Internal keyword research)
what does globaldata do: 20
globaldata competitors: est. 50+
globaldata pricing: est. 100+
globaldata review: est. 50+
globaldata vs alphasense: est. 50+
is globaldata legit: est. 50+
deallus consulting: est. 100+
Note: GlobalData's US search volume (2.4K) is significantly lower than competitors like AlphaSense (27.1K) or IQVIA (40.5K), but global volume (65.4K) is competitive due to strong brand recognition in UK, India, and international markets. The $5.93 CPC — the highest among tracked pharma CI vendors — signals high commercial intent among those searching.
This section links to the most recent Vendor Intelligence Feed posts for GlobalData. Updated as new signals are published.
This profile is maintained as a living document. When new intelligence signals change any of the four Porter components — goals, strategy, assumptions, or capabilities — the relevant sections are updated. For the latest intelligence briefs on GlobalData, visit the Vendor Intelligence Feed.
© 2026 CompetitiveIntelligence.com. Independent analysis by Alex Von. All factual claims sourced with hyperlinks.